Compare SNDL & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDL | SGHT |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 312.4M | 309.6M |
| IPO Year | 2019 | 2021 |
| Metric | SNDL | SGHT |
|---|---|---|
| Price | $1.36 | $9.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $5.00 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 1.1M | 185.2K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $6.19 | $11.67 |
| Revenue Next Year | $3.08 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.17 | $3.19 |
| 52 Week High | $2.89 | $9.71 |
| Indicator | SNDL | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 51.39 | 78.57 |
| Support Level | $1.34 | $4.43 |
| Resistance Level | $1.48 | N/A |
| Average True Range (ATR) | 0.04 | 0.36 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 50.00 | 89.69 |
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.